{"id":"zonisamide-low-dose-group","safety":{"commonSideEffects":[{"rate":"15-25","effect":"Somnolence"},{"rate":"10-15","effect":"Ataxia"},{"rate":"10-15","effect":"Dizziness"},{"rate":"5-10","effect":"Anorexia"},{"rate":"5-10","effect":"Cognitive impairment"},{"rate":"1-4","effect":"Nephrolithiasis"},{"rate":"1-3","effect":"Hypohidrosis"}]},"_chembl":{"chemblId":"CHEMBL750","moleculeType":"Small molecule","molecularWeight":"212.23"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Zonisamide is a sulfonamide anticonvulsant that blocks sodium and calcium channels, reducing repetitive neuronal firing. It also inhibits carbonic anhydrase, which may contribute to its anticonvulsant effects. The drug is effective across multiple seizure types and is used as adjunctive or monotherapy in epilepsy management.","oneSentence":"Zonisamide inhibits multiple ion channels and carbonic anhydrase to reduce neuronal excitability and seizure activity.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:16:48.646Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Epilepsy (adjunctive or monotherapy for partial seizures)"},{"name":"Generalized tonic-clonic seizures"}]},"trialDetails":[{"nctId":"NCT03689114","phase":"PHASE4","title":"Low vs. Standard Daily Doses of Antiepileptic Drugs in Newly Diagnosed, Previously Untreated Epilepsy(STANDLOW)","status":"COMPLETED","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2021-05-10","conditions":"Epilepsies, Partial","enrollment":58},{"nctId":"NCT01127165","phase":"PHASE4","title":"Low and High Dose Zonisamide in Children as Monotherapy","status":"COMPLETED","sponsor":"Eisai Korea Inc.","startDate":"2006-03","conditions":"Epilepsy","enrollment":125}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"zonisamide low dose group","genericName":"zonisamide low dose group","companyName":"Eisai Korea Inc.","companyId":"eisai-korea-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Zonisamide is a small molecule that blocks the sodium channel alpha subunit, classified as a blocker. It is used as a monotherapy for partial epilepsies in children, with low and high dose groups being compared in clinical trials.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}